409 related articles for article (PubMed ID: 8759632)
1. Peptidyl anthraquinones as potential antineoplastic drugs: synthesis, DNA binding, redox cycling, and biological activity.
Gatto B; Zagotto G; Sissi C; Cera C; Uriarte E; Palù G; Capranico G; Palumbo M
J Med Chem; 1996 Aug; 39(16):3114-22. PubMed ID: 8759632
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, DNA-binding and cytotoxic properties of a bis(netropsin)-anthracenedione conjugate.
Boitte N; Pommery N; Colson P; Houssier C; Waring MJ; Hénichart JP; Bailly C
Anticancer Drug Des; 1997 Sep; 12(6):481-501. PubMed ID: 9311557
[TBL] [Abstract][Full Text] [Related]
3. Sequence selectivity of topoisomerase II DNA cleavage stimulated by mitoxantrone derivatives: relationships to drug DNA binding and cellular effects.
De Isabella P; Capranico G; Palumbo M; Sissi C; Krapcho AP; Zunino F
Mol Pharmacol; 1993 May; 43(5):715-21. PubMed ID: 8388987
[TBL] [Abstract][Full Text] [Related]
4. Rational design, synthesis, and DNA binding properties of novel sequence-selective peptidyl congeners of ametantrone.
Gianoncelli A; Basili S; Scalabrin M; Sosic A; Moro S; Zagotto G; Palumbo M; Gresh N; Gatto B
ChemMedChem; 2010 Jul; 5(7):1080-91. PubMed ID: 20458714
[TBL] [Abstract][Full Text] [Related]
5. Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza- and 2-aza-oxide-anthracenedione derivatives.
De Isabella P; Palumbo M; Sissi C; Capranico G; Carenini N; Menta E; Oliva A; Spinelli S; Krapcho AP; Giuliani FC
Mol Pharmacol; 1995 Jul; 48(1):30-8. PubMed ID: 7623772
[TBL] [Abstract][Full Text] [Related]
6. Aza-bioisosteres of 9, 10-anthracenedione: a modulation of DNA sequence specificity.
Sissi C; Capranico G; Menta E; Palumbo M
Mol Pharmacol; 1996 Oct; 50(4):838-45. PubMed ID: 8863828
[TBL] [Abstract][Full Text] [Related]
7. Free radical production and DNA cleavage by copper chelating peptide-anthraquinones.
Morier-Teissier E; Bernier JL; Lohez M; Catteau JP; Hénichart JP
Anticancer Drug Des; 1990 Aug; 5(3):291-305. PubMed ID: 2400540
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and structure-activity correlations of the cytotoxic bifunctional 1,4-diamidoanthraquinone derivatives.
Huang HS; Chiu HF; Lee AL; Guo CL; Yuan CL
Bioorg Med Chem; 2004 Dec; 12(23):6163-70. PubMed ID: 15519160
[TBL] [Abstract][Full Text] [Related]
9. Cyclopent[a]anthraquinones as DNA intercalating agents with covalent bond formation potential: synthesis and biological activity.
Kim JY; Su TL; Chou TC; Koehler B; Scarborough A; Ouerfelli O; Watanabe KA
J Med Chem; 1996 Jul; 39(14):2812-8. PubMed ID: 8709111
[TBL] [Abstract][Full Text] [Related]
10. A search for potential antitumor agents: biological effects and DNA binding of a series of anthraquinone derivatives.
Palù G; Palumbo M; Antonello C; Meloni GA; Marciani-Magno S
Mol Pharmacol; 1986 Feb; 29(2):211-7. PubMed ID: 3951432
[TBL] [Abstract][Full Text] [Related]
11. Anthracenedione-methionine conjugates are novel topoisomerase II-targeting anticancer agents with favorable drug resistance profiles.
Lee CH; Hsieh MY; Hsin LW; Chen HC; Lo SC; Fan JR; Chen WR; Chen HW; Chan NL; Li TK
Biochem Pharmacol; 2012 May; 83(9):1208-16. PubMed ID: 22306066
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, DNA binding, and cytotoxicity of 1,4-bis(2-amino-ethylamino)anthraquinone-amino acid conjugates.
Hsin LW; Wang HP; Kao PH; Lee O; Chen WR; Chen HW; Guh JH; Chan YL; His CP; Yang MS; Li TK; Lee CH
Bioorg Med Chem; 2008 Jan; 16(2):1006-14. PubMed ID: 17962028
[TBL] [Abstract][Full Text] [Related]
13. The essential role of anthraquinones as substrates for NADH dehydrogenase in their redox cycling activity.
Tarasiuk J; Garnier-Suillerot A; Stefańska B; Borowski E
Anticancer Drug Des; 1992 Aug; 7(4):329-40. PubMed ID: 1324690
[TBL] [Abstract][Full Text] [Related]
14. Topoisomerase II-mediated DNA cleavage activity and irreversibility of cleavable complex formation induced by DNA intercalator with alkylating capability.
Kong XB; Rubin L; Chen LI; Ciszewska G; Watanabe KA; Tong WP; Sirotnak FM; Chou TC
Mol Pharmacol; 1992 Feb; 41(2):237-44. PubMed ID: 1311406
[TBL] [Abstract][Full Text] [Related]
15. Substitution at the F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding, and topoisomerase I inhibition activities.
Bailly C; Qu X; Chaires JB; Colson P; Houssier C; Ohkubo M; Nishimura S; Yoshinari T
J Med Chem; 1999 Jul; 42(15):2927-35. PubMed ID: 10425102
[TBL] [Abstract][Full Text] [Related]
16. Bis-substituted hydroxy-anthracenediones: DNA binding and biological activity.
Palumbo M; Palù G; Gia O; Ferrazzi E; Gastaldi S; Antonello C; Meloni GA
Anticancer Drug Des; 1987 Apr; 1(4):337-46. PubMed ID: 3450303
[TBL] [Abstract][Full Text] [Related]
17. Conformational drug determinants of the sequence specificity of drug-stimulated topoisomerase II DNA cleavage.
Capranico G; Palumbo M; Tinelli S; Mabilia M; Pozzan A; Zunino F
J Mol Biol; 1994 Jan; 235(4):1218-30. PubMed ID: 8308885
[TBL] [Abstract][Full Text] [Related]
18. Binding of bis-substituted 2-aza-anthracenedione regioisomers to DNA: effects of the relative positioning of the side chains.
Sissi C; Moro S; Zagotto G; Ellis M; Krapcho AP; Menta E; Palumbo M
Anticancer Drug Des; 1999 Jun; 14(3):265-74. PubMed ID: 10500501
[TBL] [Abstract][Full Text] [Related]
19. New anthracenedione derivatives with improved biological activity by virtue of stable drug-DNA adduct formation.
Mansour OC; Evison BJ; Sleebs BE; Watson KG; Nudelman A; Rephaeli A; Buck DP; Collins JG; Bilardi RA; Phillips DR; Cutts SM
J Med Chem; 2010 Oct; 53(19):6851-66. PubMed ID: 20860366
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, biological activity and DNA interaction of anilinoacridine and bithiazole peptide derivatives related to the anti-tumor drugs m-AMSA and bleomycin.
Morier-Teissier E; Bailly C; Bernier JL; Houssin R; Helbecque N; Catteau JP; Colson P; Houssier C; Hénichart JP
Anticancer Drug Des; 1989 Jun; 4(1):37-52. PubMed ID: 2474298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
